PALO ALTO, June 17 — Sonire Therapeutics, a U.S.-based clinical-stage medical device company, has announced a significant development in its pursuit of non-invasive ultrasound therapies for cancer treatment. The company’s Japan-based group company, Sonire Therapeutics KK, has been selected for the New Energy and Industrial Technology Development Organization’s (NEDO) Deep-Tech Startups Support Program (DTSU), securing non-dilutive funding to support the commercialization, development, and expansion strategy for its Ultrasound-Guided HIFU Platform. This funding will be instrumental in advancing the global commercialization of Sonire’s pancreatic cancer treatment.
The treatment involves using high-intensity focused ultrasound (HIFU) guided by ultrasound imaging to target and destroy cancer cells without invasive surgery. What is notable is the potential of ultrasound-guided HIFU to provide a non-invasive alternative to traditional cancer treatments.
The mechanism of how it works involves focusing sound waves onto a specific area of the tumor, generating heat that destroys cancer cells while sparing surrounding healthy tissue. A key aspect of Sonire Therapeutics’ strategy is the development of its Ultrasound-Guided HIFU Platform, designed to improve the accuracy and efficacy of HIFU treatments. The platform utilizes advanced ultrasound imaging to guide the delivery of HIFU energy, allowing for real-time monitoring and adjustment of the treatment.
As Sonire Therapeutics moves forward with the commercialization of its pancreatic cancer treatment, it will be crucial to watch how the company leverages the funding from the NEDO DTSU program to expand its development and expansion strategy. The success of this treatment could offer new hope for patients with pancreatic cancer.
Looking ahead, the progress of Sonire Therapeutics in advancing its Ultrasound-Guided HIFU Platform will be an important development to follow, as it has the potential to bring new treatment options to patients with pancreatic cancer and possibly other types of cancer in the future. Consult your doctor for medical advice.
